National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/4855

TDMS Study 96002-02 Pathology Tables

NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00
Route: SKIN APPLICATION                                                                                           Time: 08:19:20

                                                 FINAL#1; 17 DAY REPEATED DOSE




       Facility:  BIORELIANCE

       Chemical CAS #:  136-35-6

       Lock Date:  01/21/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                           5            5            5            5            5            5           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                                                                                  2           
    Natural Death                                                                                                       1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                 5            5            5            5            5            2           
                                                                                                                                    
  Animals Examined Microscopically                     5            5            5            5            5            5           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Inflammation, Focal                              5 (100%)     5 (100%)     4 (80%)      1 (20%)      1 (20%)      1 (20%)     
      Necrosis, Focal                                                                                                   2 (40%)     
      Hepatocyte, Vacuolization Cytoplasmic                                                                             1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Atrium, Thrombosis                                                                                   1 (20%)      2 (40%)     
      Myocardium, Ventricle, Mineralization                                                                             1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
   Bone Marrow                                        (5)                                                 (5)          (5)          
      Myeloid Cell, Hyperplasia                                                                                         1 (20%)     
   Lymph Node, Mandibular                             (4)          (5)          (5)          (5)          (4)          (4)          
      Atrophy                                                                                                           3 (75%)     
   Lymph Node, Mesenteric                             (5)          (5)          (5)          (5)          (3)          (4)          
      Atrophy                                                                                              1 (33%)      1 (25%)     
   Spleen                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Hematopoietic Cell Proliferation                              5 (100%)     5 (100%)     5 (100%)     2 (40%)      2 (40%)     
      Lymphoid Follicle, Atrophy                                                                           3 (60%)      2 (40%)     
   Thymus                                             (5)          (5)          (5)          (5)          (5)          (4)          
      Atrophy                                                                                 4 (80%)      5 (100%)     3 (75%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (5)          (5)          (5)          (5)          (5)          (5)          
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia                                               5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Hair Follicle, Skin, Site of Application,                                                                                     
           Hyperplasia                                              5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Skin, Site of Application, Inflammation                       5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Skin, Site of Application, Ulcer                                           1 (20%)      2 (40%)      4 (80%)      2 (40%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (5)                                                 (5)          (5)          
      Artery, Inflammation                                                                                              1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Bilateral, Cortex, Renal Tubule, Dilatation                                                                       4 (80%)     
      Bilateral, Cortex, Renal Tubule, Necrosis                                                            4 (80%)      1 (20%)     
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                           5            5            5            5            5            5           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                                                        4            5            5           
  Survivors                                                                                                                         
    Terminal Sacrifice                                 5            5            5            1                                     
                                                                                                                                    
  Animals Examined Microscopically                     5            5            5            5            5            5           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Inflammation, Focal                                           4 (80%)      1 (20%)      1 (20%)                   1 (20%)     
      Mineralization                                   1 (20%)                                                                      
      Necrosis, Focal                                                                                      3 (60%)      5 (100%)    
      Hepatocyte, Vacuolization Cytoplasmic                                                                1 (20%)      1 (20%)     
   Stomach, Forestomach                               (5)          (5)          (5)          (5)          (5)          (5)          
      Ulcer, Focal                                                                                         2 (40%)      2 (40%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (5)          (5)          (5)          (5)          (5)          (5)          
      Atrium, Thrombosis                                                                      2 (40%)      5 (100%)     5 (100%)    
      Myocardium, Atrium, Mineralization                                                                                1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Penis                                                                                     (2)          (1)          (1)          
      Congestion                                                                              1 (50%)                               
   Testes                                             (5)          (5)          (5)          (5)          (5)          (5)          
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - CONT                                                                                                               
      Germinal Epithelium, Degeneration                                                                    2 (40%)      1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (5)                       (5)          (5)          (5)          (5)          
      Myeloid Cell, Hyperplasia                                                                            1 (20%)                  
   Lymph Node, Mandibular                             (5)          (5)          (5)          (5)          (4)          (5)          
      Atrophy                                                                                 3 (60%)      4 (100%)     5 (100%)    
   Lymph Node, Mesenteric                             (4)          (5)          (4)          (5)          (5)          (4)          
      Atrophy                                                                                 2 (40%)      3 (60%)      4 (100%)    
   Spleen                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Hematopoietic Cell Proliferation                              5 (100%)     5 (100%)     2 (40%)      1 (20%)                  
      Lymphoid Follicle, Atrophy                                                              1 (20%)      2 (40%)      5 (100%)    
   Thymus                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Atrophy                                                                                 5 (100%)     5 (100%)     5 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (5)          (5)          (5)          (5)          (5)          (5)          
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia                                               5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Epidermis, Skin, Site of Application,                                                                                         
          Inflammation, Focal                          1 (20%)                                                                      
      Hair Follicle, Skin, Site of Application,                                                                                     
           Hyperplasia                                              5 (100%)     5 (100%)     5 (100%)     5 (100%)     2 (40%)     
      Skin, Site of Application, Inflammation                       5 (100%)     5 (100%)     5 (100%)     5 (100%)     5 (100%)    
      Skin, Site of Application, Ulcer                              1 (20%)      1 (20%)      1 (20%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    6                                                              
                                                                                                                                   
NTP Experiment-Test: 96002-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: 14DAY REPEATED                               DIAZOAMINOBENZENE (DAAB)                                 Date: 09/27/00    
Route: SKIN APPLICATION                                                                                           Time: 08:19:20    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          0 MG/KG      12.5         25 MG/KG     50 MG/KG     100          200             
                                                                MG/KG                                  MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - CONT                                                                                                           
   Lung                                               (5)                       (5)          (5)          (5)          (5)          
      Artery, Mineralization                                                                                            1 (20%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (5)          (5)          (5)          (5)          (5)          (5)          
      Bilateral, Cortex, Renal Tubule, Necrosis                                                            5 (100%)     5 (100%)    
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    7                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.